Royal Bank Of Canada Lifts ResMed Price Target to $244

ResMed's stock received an updated price target of $244 from Royal Bank Of Canada. This new forecast presents a potential upside of 15.18% from the company's previous close.

The brokerage has maintained its 'sector perform' rating on ResMed, which is a medical equipment provider focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions.

Other analysts have also recently issued reports about the company. Citigroup reaffirmed a 'neutral' rating and set a $235 price target, while Mizuho decreased its target price on ResMed from $235 to $220 and set an 'outperform' rating for the company.